1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
ME/CFS and the Magic of the Canine Factor
There's been plenty of research indicating that having pets is good for your health. I never really noticed any particular benefits to having cats, though that may have had more to do with my cats. They've been fairly indifferent to my presence and we've shared a live-and-let-live...
Discuss the article on the Forums.

Phoenix Rising tweeting live now from Invest in ME 2014 Conference 30 May

Discussion in 'General ME/CFS News' started by Sasha, May 30, 2014.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    8,043
    Likes:
    6,835
    UK
    I guess that's our lot.

    Thanks, @Mark - you did a fantastic job! Hope you enjoyed the conference. :thumbsup:

    Can't wait to get the DVDs now. Last year it took a couple of months at least, I think.
    aimossy, NK17 and Bob like this.
  2. Valentijn

    Valentijn Activity Level: 3

    Messages:
    6,265
    Likes:
    8,941
    Amersfoort, Netherlands
    Disproportional according to what? The ME patients I've seen data for are about the same as non-patients, and I don't recall any research into the subject showing otherwise.
    SOC likes this.
  3. Nielk

    Nielk

    Messages:
    5,242
    Likes:
    5,139
    Queens, NY
    I don't know @Valentijn - I just copied it from PR's tweet.
    Valentijn likes this.
  4. Countrygirl

    Countrygirl Senior Member

    Messages:
    819
    Likes:
    589
    UK
    Thank you, Mark. I appreciate being kept informed. :thumbsup:
    WillowJ likes this.
  5. Sushi

    Sushi Moderator and Senior Member Albuquerque

    Messages:
    6,876
    Likes:
    5,715
    Albuquerque
    Yasko found a very high % of ME patients had an MTHFR SNP--don't have the stats though.

    Sushi
  6. Helen

    Helen Senior Member

    Messages:
    493
    Likes:
    453
    Did you, or anyone, get who of the lecturers that told this?

    Thanks @Mark and everyone for reporting from the conference.
    Last edited: May 30, 2014
  7. Kina

    Kina Moderation Team Lead

    Messages:
    5,525
    Likes:
    4,052
    Ontario, Canada
    Dr. Andreas Kogelnik.
    Helen and Valentijn like this.
  8. NK17

    NK17 Senior Member

    Messages:
    399
    Likes:
    858
    My ME specialist Dr. Kogelnik is starting a clinical study based on his clinic's patient population MTHFR test results.
    As far as I know he tests all his patients. I'm heterozygous for one mutation, have been supplementing with sublingual methylcobalamine and L-methylfolate (Solgar).
    Helen likes this.
  9. Valentijn

    Valentijn Activity Level: 3

    Messages:
    6,265
    Likes:
    8,941
    Amersfoort, Netherlands
    I wouldn't take anything from Yasko seriously. She has proven that she can't be trusted to read and interpret research, so I can't say I have a lot of faith in her counting abilities either.

    We do have a fair number of MTHFR and MTRR mutations which can have a significant impact in gene functionality, but so does everyone else. They're fairly common ones, usually in excess of 10% prevalence in homozygous form in the general population, and 40%+ as heterozygous.

    It's an interesting area, and I think treating existing methylation problems can be significantly helpful. But it isn't helpful when prevalence and efficacy claims are being so badly exaggerated. It gives the impression that 1) we're a bit hysterical on the subject and 2) we can easily be cured with a couple vitamins (or a dozen over-priced items from Yasko's webshop).
    Last edited: Jun 2, 2014
    beaker, cigana, SOC and 6 others like this.
  10. aimossy

    aimossy Senior Member

    Messages:
    1,992
    Likes:
    2,451
    NZ
    Where were Fluge and Mella?(I can not remember spelling) Was this embargoed info at the conference?
    I must admit I am going to be very disappointed if there is no publishing of papers this year.
    I think "very soon" or "imminent" statements about publishing is not really fair and they should be more honest and realistic with patients.
    Ninan, RL_sparky and Firestormm like this.
  11. Kati

    Kati Patient in training

    Messages:
    1,975
    Likes:
    1,302
    i agree with you @Valentijn. i am looking forward to blinded clinical trials results from Dr K whenever that will be ready. Everything needs to be backed up by solid research.
    SOC, NK17 and Valentijn like this.
  12. natasa778

    natasa778 Senior Member

    Messages:
    1,410
    Likes:
    1,209
    London UK
    Kogelnik
    Helen likes this.
  13. natasa778

    natasa778 Senior Member

    Messages:
    1,410
    Likes:
    1,209
    London UK
    I believe he said (but was talking very fast, and this is from memory as wasn't taking notes by that point :) that they did deep sequencing and found certain MTHFR in 90% of CFS/ME samples, whereas they are present in only 30% of general population.

    So not causative but if replicated over larger number of samples paints a good picture of vulnerability/risk.
    SOC, Helen, Kati and 3 others like this.
  14. Kate_UK

    Kate_UK Senior Member

    Messages:
    232
    Likes:
    228
    They were due to speak the day before, see here http://www.investinme.eu/news.html

    Ninan, NK17 and aimossy like this.
  15. aimossy

    aimossy Senior Member

    Messages:
    1,992
    Likes:
    2,451
    NZ
    Thanks @Kate_UK I got mixed up and thought they were speaking on the second day.
  16. Kina

    Kina Moderation Team Lead

    Messages:
    5,525
    Likes:
    4,052
    Ontario, Canada
    He actually said 95 percent of the ME samples and about 40 percent of the general population.
    searcher, Sushi, SOC and 4 others like this.
  17. Firestormm

    Firestormm Guest

    Messages:
    5,824
    Likes:
    5,974
    Cornwall England
    Anyone know if they said anything about why the announced paper at the conference last year has not yet been published a year later? Thanks
  18. Kate_UK

    Kate_UK Senior Member

    Messages:
    232
    Likes:
    228
  19. Mark

    Mark Acting CEO

    Messages:
    4,527
    Likes:
    2,004
    Sofa, UK
    No embargoed information was presented this year.

    I think there are a lot of groups hard at work right now, and they will publish when the time is right, but I agree it's very frustrating when interesting or exciting research that is presented as embargoed doesn't reach the light of day and get published. I suppose there are many possible explanations for that and it probably doesn't do any of us any favours to delve deeply into why.
    NK17 likes this.
  20. Mark

    Mark Acting CEO

    Messages:
    4,527
    Likes:
    2,004
    Sofa, UK
    My guess - and it really is a complete guess - is that they encountered some difficulties finding a high-profile publisher for the follow-up study which had basically the same results as the first study, and pretty soon they found they were then into a whole new ball-game - funding and preparation for the big multicentre follow-up study must have been the top priority, and with the UK Rituximab study getting funded, we now have at least two replication studies in progress for the Rituximab results. So what would be the benefit of publishing the 2nd Rituximab study now? Minimal, perhaps...and maybe the cost/benefit just didn't justify the time it would have taken to complete it. I can certainly relate to the experience of being absolutely committed to doing something, and planning to do it, and then finding myself snowed under with even higher priorities arising from the original plan. One thing I'm confident of, they and our other top researchers are committed to progressing the science of ME/CFS as soon as possible, and all the researchers I've met are passionate and engaged and determined, and they have a lot more understanding than I do about the detail of these issues. I'd like to see that follow-up study published, but the two Rituximab replication studies are far more important...if it's a question of where to spend limited time, the two replication studies have to be their top priority...
    beaker and NK17 like this.

See more popular forum discussions.

Share This Page